Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aspreva Pharmaceuticals Corporation has reported that its shareholders and optionholders have approved the proposed acquisition of the company by Galenica Group, through a wholly owned Canadian subsidiary, at a price of $26 per share in cash.
Subscribe to our email newsletter
At the special meeting of securityholders, the transaction was approved by over 99% of the votes cast by shareholders and by over 99% of the votes cast by shareholders and optionholders, voting together as a class.
Subject to court approval being obtained, receipt of approval by the Minister of Industry under the Investment Canada Act and the other conditions to closing being satisfied or waived, the transaction is expected to close on January 3, 2008.
Shareholders also approved an amendment to Aspreva’s shareholder rights plan in order to facilitate the proposed acquisition of Aspreva by Galenica Group.